DSM-Firmenich AG

DSFIR: XAMS (NLD)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
xYZLOCK|YZKLOCK|brdDW$j

DSM-Firmenich Earnings: Solid First Half With Good Progress on Innovation and Synergy Realization

DSM-Firmenich reported first-half 2025 organic sales growth of 7% and EBITDA of EUR 1,260 million, 29% higher than the prior year. The results align with the company-compiled consensus, and management confirmed the full-year guidance.

Sponsor Center